Alzheimer's disease progression model based on integrated biomarkers and clinical measures

Aim:Biomarkers and image markers of Alzheimer's disease (AD), such as cerebrospinal fluid Aβ42 and p-tau, are effective predictors of cognitive decline or dementia. The aim of this study was to integrate these markers with a disease progression model and to identify their abnormal ranges.Methods:The data of 395 participants, including 86 normal subjects, 108 early mild cognitive impairment (EMCI) subjects, 120 late mild cognitive impairment (LMCI) subjects, and 81 AD subjects were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. For the participants, baseline and long-term data on cerebrospinal fluid Aβ42 and p-tau, hippocampal volume, and ADAS-cog were available. Various linear and nonlinear models were tested to determine the associations among the ratio of Aβ42 to p-tau (the Ratio), hippocampal volume and ADAS-cog.Results:The most likely models for the Ratio, hippocampal volume, and ADAS-cog (logistic, Emax, and linear models, respectively) were used to construct the final model. Baseline disease state had an impact on all the 3 endpoints (the Ratio, hippocampal volume, and ADAS-cog), while APOEε4 genotype and age only influence the Ratio and hippocampal volume.Conclusion:The Ratio can be used to identify the disease stage for an individual, and clinical measures integrated with the Ratio improve the accuracy of mild cognitive impairment (MCI) to AD conversion forecasting.

[1]  J. Price,et al.  Cerebral amyloid deposition and diffuse plaques in ``normal'' aging , 1996, Neurology.

[2]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[3]  Richard S. J. Frackowiak,et al.  A voxel‐based morphometry study of semantic dementia: Relationship between temporal lobe atrophy and semantic memory , 2000, Annals of neurology.

[4]  G. B. Frisoni,et al.  The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort , 2010, Neurobiology of Aging.

[5]  D. Rubinsztein,et al.  Therapeutic induction of autophagy to modulate neurodegenerative disease progression , 2013, Acta Pharmacologica Sinica.

[6]  H. Braak,et al.  Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship , 2009, Journal of neuropathology and experimental neurology.

[7]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[8]  Jian-Zhi Wang,et al.  Role of melatonin in Alzheimer-like neurodegeneration , 2006, Acta Pharmacologica Sinica.

[9]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[10]  G. Glenner,et al.  Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. , 1984, Biochemical and biophysical research communications.

[11]  Michael Gold,et al.  Modeling Alzheimer’s disease progression using the disease system analysis approach , 2012, Alzheimer's & Dementia.

[12]  V. Lobanov,et al.  An Improved Model for Disease Progression in Patients From the Alzheimer's Disease Neuroimaging Initiative , 2012, Journal of clinical pharmacology.

[13]  J. Trojanowski,et al.  Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics , 2007, Nature Reviews Drug Discovery.

[14]  K E Peace,et al.  Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[15]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[16]  Jesse S. Jin,et al.  Identification of Conversion from Mild Cognitive Impairment to Alzheimer's Disease Using Multivariate Predictors , 2011, PloS one.

[17]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[18]  Henrik Zetterberg,et al.  Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer’s Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study , 2012, PloS one.

[19]  W. M. van der Flier,et al.  Joint effect of hypertension and APOE genotype on CSF biomarkers for Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[20]  C. Jack,et al.  Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance , 2012, Neurobiology of Aging.

[21]  Kiralee M. Hayashi,et al.  Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. , 2006, Archives of neurology.

[22]  Zhen-yu Yue,et al.  Autophagy in ageing and ageing-associated diseases , 2013, Acta Pharmacologica Sinica.

[23]  C. Duyckaerts,et al.  Dissociation of Alzheimer type pathology in a disconnected piece of cortex , 1997, Acta Neuropathologica.

[24]  Jian-Zhi Wang,et al.  Alzheimer-like tau phosphorylation induced by wortmannin in vivo and its attenuation by melatonin. , 2002, Acta pharmacologica Sinica.

[25]  D. Mould.  Models for Disease Progression: New Approaches and Uses , 2012, Clinical pharmacology and therapeutics.

[26]  S. Duchesne,et al.  Toward a dynamic biomarker model in Alzheimer's disease. , 2012, Journal of Alzheimer's Disease.

[27]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative , 2008 .

[28]  Charles DeCarli,et al.  Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? , 2003, Archives of neurology.

[29]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[30]  P. S. Mathuranath,et al.  An overview of biomarkers in Alzheimer’s disease , 2010, Annals of Indian Academy of Neurology.

[31]  Wenhua Zheng,et al.  Neuroprotective effects of resveratrol against β‐amyloid‐induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C , 2004, British journal of pharmacology.